FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2468426875> ?p ?o ?g. }

• W2468426875 endingPage "4003" @default.
• W2468426875 startingPage "3997" @default.
• W2468426875 abstract "Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report Bing Sun,1 Lijuan Ding,1 Shikai Wu,1 Xiangying Meng,1 Santai Song2 1Department of Radiotherapy, 2Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, People’s Republic of China Background: Everolimus, an inhibitor of the mammalian target of rapamycin, shows promising antitumor activity when combined with trastuzumab and chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer or when combined with endocrine agents for hormone receptor (HR)-positive tumors. However, data are limited regarding the effect of everolimus in combination with endocrine drugs in HER2-positive advanced breast cancer regardless of the HR status.Case presentation: A 44-year-old female was diagnosed with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant, a selective estrogen receptor downregulator, was chosen to reverse the resistance to anti-HER2 therapy. Indeed, the patient experienced long-term disease stabilization. Adverse events associated with the treatment were manageable by dose adjustments. We performed genetic testing of the metastatic tumor, which harbored a PIK3CA gene mutation but was positive for phosphatase and tensin homologue expression, which might result in resistance to the mammalian target of rapamycin inhibitor.Conclusion: This case study indicates that combined treatment with everolimus and fulvestrant might be a viable option for the treatment of metastatic breast cancer patients who are HER2 positive and carry a PIK3CA gene mutation but are resistant to anti-HER2 therapy and classical chemotherapeutic agents. Further prospective randomized trials are needed to confirm this finding. Keywords: mTOR inhibitor, PIK3CA gene, genetic testing, PI3K Akt mTOR pathway" @default.
• W2468426875 created "2016-07-22" @default.
• W2468426875 creator A5008171523 @default.
• W2468426875 creator A5016717762 @default.
• W2468426875 creator A5017359407 @default.
• W2468426875 creator A5029565498 @default.
• W2468426875 creator A5081301252 @default.
• W2468426875 date "2016-07-01" @default.
• W2468426875 modified "2023-09-25" @default.
• W2468426875 title "Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report" @default.
• W2468426875 cites W155933052 @default.
• W2468426875 cites W2020372547 @default.
• W2468426875 cites W2036950786 @default.
• W2468426875 cites W2037317523 @default.
• W2468426875 cites W2055275065 @default.
• W2468426875 cites W2072851956 @default.
• W2468426875 cites W2081098900 @default.
• W2468426875 cites W2094073838 @default.
• W2468426875 cites W2102620699 @default.
• W2468426875 cites W2103808574 @default.
• W2468426875 cites W2105196235 @default.
• W2468426875 cites W2113458582 @default.
• W2468426875 cites W2121917721 @default.
• W2468426875 cites W2149218373 @default.
• W2468426875 cites W2167188058 @default.
• W2468426875 cites W2169689529 @default.
• W2468426875 doi "https://doi.org/10.2147/ott.s104398" @default.
• W2468426875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4936809" @default.
• W2468426875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27445490" @default.
• W2468426875 hasPublicationYear "2016" @default.
• W2468426875 type Work @default.
• W2468426875 sameAs 2468426875 @default.
• W2468426875 citedByCount "8" @default.
• W2468426875 countsByYear W24684268752016 @default.
• W2468426875 countsByYear W24684268752017 @default.
• W2468426875 countsByYear W24684268752018 @default.
• W2468426875 countsByYear W24684268752019 @default.
• W2468426875 countsByYear W24684268752021 @default.
• W2468426875 crossrefType "journal-article" @default.
• W2468426875 hasAuthorship W2468426875A5008171523 @default.
• W2468426875 hasAuthorship W2468426875A5016717762 @default.
• W2468426875 hasAuthorship W2468426875A5017359407 @default.
• W2468426875 hasAuthorship W2468426875A5029565498 @default.
• W2468426875 hasAuthorship W2468426875A5081301252 @default.
• W2468426875 hasBestOaLocation W24684268751 @default.
• W2468426875 hasConcept C121608353 @default.
• W2468426875 hasConcept C126322002 @default.
• W2468426875 hasConcept C143998085 @default.
• W2468426875 hasConcept C2776215463 @default.
• W2468426875 hasConcept C2777176818 @default.
• W2468426875 hasConcept C2778504769 @default.
• W2468426875 hasConcept C2779699572 @default.
• W2468426875 hasConcept C2779786085 @default.
• W2468426875 hasConcept C2780482068 @default.
• W2468426875 hasConcept C2781164504 @default.
• W2468426875 hasConcept C530470458 @default.
• W2468426875 hasConcept C71924100 @default.
• W2468426875 hasConcept C84606932 @default.
• W2468426875 hasConceptScore W2468426875C121608353 @default.
• W2468426875 hasConceptScore W2468426875C126322002 @default.
• W2468426875 hasConceptScore W2468426875C143998085 @default.
• W2468426875 hasConceptScore W2468426875C2776215463 @default.
• W2468426875 hasConceptScore W2468426875C2777176818 @default.
• W2468426875 hasConceptScore W2468426875C2778504769 @default.
• W2468426875 hasConceptScore W2468426875C2779699572 @default.
• W2468426875 hasConceptScore W2468426875C2779786085 @default.
• W2468426875 hasConceptScore W2468426875C2780482068 @default.
• W2468426875 hasConceptScore W2468426875C2781164504 @default.
• W2468426875 hasConceptScore W2468426875C530470458 @default.
• W2468426875 hasConceptScore W2468426875C71924100 @default.
• W2468426875 hasConceptScore W2468426875C84606932 @default.
• W2468426875 hasLocation W24684268751 @default.
• W2468426875 hasLocation W24684268752 @default.
• W2468426875 hasLocation W24684268753 @default.
• W2468426875 hasLocation W24684268754 @default.
• W2468426875 hasOpenAccess W2468426875 @default.
• W2468426875 hasPrimaryLocation W24684268751 @default.
• W2468426875 hasRelatedWork W1979196695 @default.
• W2468426875 hasRelatedWork W2007182497 @default.
• W2468426875 hasRelatedWork W2037739232 @default.
• W2468426875 hasRelatedWork W2061368923 @default.
• W2468426875 hasRelatedWork W2084259226 @default.
• W2468426875 hasRelatedWork W2148647353 @default.
• W2468426875 hasRelatedWork W3026744143 @default.
• W2468426875 hasRelatedWork W3216352272 @default.
• W2468426875 hasRelatedWork W4361954265 @default.
• W2468426875 hasRelatedWork W4361959034 @default.
• W2468426875 hasVolume "Volume 9" @default.
• W2468426875 isParatext "false" @default.
• W2468426875 isRetracted "false" @default.
• W2468426875 magId "2468426875" @default.
• W2468426875 workType "article" @default.